Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Abstract : INTRODUCTION: Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression. We analyzed a group of 58 transcriptionally defined MA tumors and proposed a new tool to identify these tumors. METHODS: We performed quantitative reverse transcription PCR (qRT-PCR) for ESR1, AR, FOXA1 and AR-related genes, and immunohistochemistry (IHC) for ER, PR, Human Epidermal Growth Factor Receptor 2 (HER2), CK5/6, CK17, EGFR, Ki67, AR, FOXA1 and GCDFP15 and we analyzed clinical features. RESULTS: MA tumors were all characterized by ESR1(-) AR(+) FOXA1(+) and AR-related genes positive mRNA profile. IHC staining on these tumors showed 93% ER(-), only 58% AR(+) and 90% FOXA1(+). 67% and 57% MA tumors were HER2(3+) and GCDFP15(+), respectively. Almost all MA tumors (94%) had the IHC signature HER2(3+) or GCDFP15(+) but none of the 13 control basal-like (BL) tumors did. Clinically, MA tumors were rather aggressive, with poor prognostic factors. CONCLUSION: MA tumors could be better defined by their qRT-PCR-AR profile than by AR IHC. In addition, we found that HER2 or GCDFP15 protein overexpression is a sensitive and specific tool to differentiate MA from BL in the context of ER negative tumors. A composite molecular and IHC signature could, therefore, help to identify MA tumors in daily practice.
Type de document :
Article dans une revue
Breast Cancer Research, BioMed Central, 2013, 15 (3), pp.R37. 〈10.1186/bcr3421〉
Liste complète des métadonnées

Littérature citée [41 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00850498
Contributeur : Ed. Bmc <>
Soumis le : mardi 6 août 2013 - 21:09:26
Dernière modification le : jeudi 15 mars 2018 - 10:12:30
Document(s) archivé(s) le : mercredi 5 avril 2017 - 19:44:23

Fichiers

bcr3421.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

Citation

Jacqueline Lehmann-Che, Anne-Sophie Hamy, Raphaël Porcher, Marc Barritault, Fatiha Bouhidel, et al.. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.. Breast Cancer Research, BioMed Central, 2013, 15 (3), pp.R37. 〈10.1186/bcr3421〉. 〈inserm-00850498〉

Partager

Métriques

Consultations de la notice

354

Téléchargements de fichiers

541